To understand the molecular mechanism by which osimertinib decreases Topo IIα levels in EGFRm NSCLC cells, we studied mRNA levels and found that osimertinib did not alter TOP2A mRNA levels (Figure 4A), suggesting a possible posttranscriptional mechanism. This evidence concerns the gene TOP2A and non-small cell lung carcinoma.